Articles producció científica> Medicina i Cirurgia

Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia

  • Identification data

    Identifier: imarina:6858226
    Authors:
    Martin-Loeches I, Bisanti A, Diaz E, Rodriguez A
    Abstract:
    © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Patients admitted to hospitals are at risk of developing nosocomial infections. These types of infections typically occur in immune compromised patients. Furthermore, nosocomial infections are frequently caused by resistant organisms, including nonfermenting gram-negative bacilli such as Pseudomonas aeruginosa. Areas covered: P. aeruginosa is a hazardous pathogen. It can resist numerous antibiotics, due to several resistance mechanisms. It is associated with serious illnesses, particularly hospital acquired infections including ventilator associated pneumonia. In the past, only a limited number of anti-pseudomonal drugs were available. However, several therapeutic advancements have been made, in recent years, to target P. aeruginosa, including the development of the new cephalosporin: ceftolozane-tazobactam. Expert opinion: Ceftolozane-tazobactam is a combination of a novel semi-synthetic fifth generation cephalosporin with a well-established beta-lactamase inhibitor. From a structural perspective, ceftolozane-tazobactam has attested increased stability to AmpC β-lactamases. Additionally, ceftolozane-tazobactam is less affected by changes in efflux pumps and porin permeability due to an enhanced affinity to certain penicillin-binding proteins (PBPs). This enables the molecule to overcome the most common anti-drug resistant mechanisms of bacteria. According to previous clinical trials conducted, ceftolozane-tazobactam must be considered when treating patients with confirmed or suspected P. aeruginosa respiratory tract infections, either nosocomial pneumonia or ventilator-associated pneumonia.
  • Others:

    Author, as appears in the article.: Martin-Loeches I, Bisanti A, Diaz E, Rodriguez A
    Department: Medicina i Cirurgia
    URV's Author/s: Rodríguez Oviedo, Alejandro Hugo
    Keywords: Vat Vap Urinary-tract-infections Sepsis Safety Resistance Renal-function Pseudomonas-aeruginosa Population pharmacokinetics Pneumonia Plus metronidazole P. aeruginosa P Multicenter Double-blind Cephalosporin Aeruginosa
    Abstract: © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Patients admitted to hospitals are at risk of developing nosocomial infections. These types of infections typically occur in immune compromised patients. Furthermore, nosocomial infections are frequently caused by resistant organisms, including nonfermenting gram-negative bacilli such as Pseudomonas aeruginosa. Areas covered: P. aeruginosa is a hazardous pathogen. It can resist numerous antibiotics, due to several resistance mechanisms. It is associated with serious illnesses, particularly hospital acquired infections including ventilator associated pneumonia. In the past, only a limited number of anti-pseudomonal drugs were available. However, several therapeutic advancements have been made, in recent years, to target P. aeruginosa, including the development of the new cephalosporin: ceftolozane-tazobactam. Expert opinion: Ceftolozane-tazobactam is a combination of a novel semi-synthetic fifth generation cephalosporin with a well-established beta-lactamase inhibitor. From a structural perspective, ceftolozane-tazobactam has attested increased stability to AmpC β-lactamases. Additionally, ceftolozane-tazobactam is less affected by changes in efflux pumps and porin permeability due to an enhanced affinity to certain penicillin-binding proteins (PBPs). This enables the molecule to overcome the most common anti-drug resistant mechanisms of bacteria. According to previous clinical trials conducted, ceftolozane-tazobactam must be considered when treating patients with confirmed or suspected P. aeruginosa respiratory tract infections, either nosocomial pneumonia or ventilator-associated pneumonia.
    Thematic Areas: Virology Saúde coletiva Química Pharmacology & pharmacy Microbiology (medical) Microbiology Medicina ii Medicina i Infectious diseases Farmacia Engenharias iv Enfermagem Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biodiversidade
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 14787210
    Author's mail: alejandrohugo.rodriguez@urv.cat
    Author identifier: 0000-0001-8828-5984
    Record's date: 2023-09-02
    Papper version: info:eu-repo/semantics/acceptedVersion
    Link to the original source: https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1794816?needAccess=true
    Papper original source: Expert Review Of Anti-Infective Therapy. 18 (12): 1-9
    APA: Martin-Loeches I, Bisanti A, Diaz E, Rodriguez A (2020). Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia. Expert Review Of Anti-Infective Therapy, 18(12), 1-9. DOI: 10.1080/14787210.2020.1794816
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Article's DOI: 10.1080/14787210.2020.1794816
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2020
    Publication Type: Journal Publications
  • Keywords:

    Infectious Diseases,Microbiology,Microbiology (Medical),Pharmacology & Pharmacy,Virology
    Vat
    Vap
    Urinary-tract-infections
    Sepsis
    Safety
    Resistance
    Renal-function
    Pseudomonas-aeruginosa
    Population pharmacokinetics
    Pneumonia
    Plus metronidazole
    P. aeruginosa
    P
    Multicenter
    Double-blind
    Cephalosporin
    Aeruginosa
    Virology
    Saúde coletiva
    Química
    Pharmacology & pharmacy
    Microbiology (medical)
    Microbiology
    Medicina ii
    Medicina i
    Infectious diseases
    Farmacia
    Engenharias iv
    Enfermagem
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Biotecnología
    Biodiversidade
  • Documents:

  • Cerca a google

    Search to google scholar